Friday, July 14, 2017

Zero-fat, clean, lab-made chicken on the way



Here is the good news for the non-vegetarians. Very hygienic, healthy and tasty laboratory-made chicken is coming soon into the Indian market. Research by biotechnology scientists proved that chicken can be made in the lab with same qualities, colour and taste as natural chicken. Moreover, the laboratory made chicken will be zero-fat. 

The first phase of the laboratory chicken (cultured or artificial chicken) research project was successfully completed at GITAM University. There are some satellite cells in human and animals. The cells are born automatically and healthy. These cells have unique feature that they can be developed or changed into any other cells in body. 


 



Sunday, July 9, 2017

'Include local advice for drug trials in India'


'Include local advice for drug trials in India'












Clinical trials done in India should be guided by local concerns and have a strong local participation, felt Roy Rampling, eminent neuro-oncologist and researcher. Delivering the Tata oration in clinical oncology on Friday, Rampling -a professor at the University of Glasgow -said he was surprised to find that clinical trials in India were often controlled entirely by foreign agencies and local investigators had no say in deciding their courses. "All trials are done in India should include local advise. It should be designed for the gain of the local community," said the Malta-born Rampling.

Describing India as the ideal venue for clinical trials, Rampling said the country was ready to take off in medical research...

Saturday, July 8, 2017

Is ‘Right-to-try’ bill right?

The bill would exempt doctors and drug companies from liability of prescribing and supplying experimental drugs
​.



image courtesy: Scienceblogs

'Right-to-try' is being debated fiercely in US as the American Congress is considering a bill on the topic. It is a practice allowing patients diagnosed with terminal illnesses to use drugs that are yet to be approved and are out of clinical trials, but have passed the first clinical test of safety. However, usage of even such drugs also requires Food & Drugs Administration (FDA) approval. The bill in the US Congress however, seeks to eliminate this FDA approval and monitoring of the process.

The Trump administration has supported the bill and this is termed by many as a part of the administration's passion for deregulation. In all 33 states have already passed 'Right-to-try' laws. Efforts of Goldwater institute, a libertarian non-profit organisation that drafted the model law, have led to passing of the laws in the states. In general, overall anti-regulatory environment in the society appears to have provided strength to the 'Right-to-try' moment.

Those supporting the bill claim that as it is the terminally ill patients have no hope for cure from the regular drugs that are given to them. So, why not allow them to try new drugs though it is little risky proposition as all stages of clinical trials are not completed yet. In the process of receiving approval after completing all phases of trials, the drug will be available after long time. But if allowed it to use before that it may be successful in some cases and save life to terminally ill patient.



Thursday, July 6, 2017

India Contract Research Organization Market, is projected to grow at a CAGR of 20.4% and is expected to reach US$ 6,310.5 million by 2022

Market Research Future published a Statistic research report on India Contract Research Organization Market, from 2017 to 2022″ – Market Analysis, Scope, Stake, Progress, Trends and Forecast to 2023.

India Contract Research Organization Market, is projected to grow at a CAGR of 20.4% and is expected to reach US$ 6,310.5 million by 2022. In India contract research organization market, drug development/clinical trials accounted for the largest market share in 2016.

A Contract Research Organization (CRO) is a service association that offers help to the pharmaceutical business and offers an extensive variety of outsourced pharmaceutical research administrations to help in R&D system and in this way a basic tool for undertaking clinical trials in the present situation when high stakes are included in the drug discovery process. This industry likewise offers a safe choice of venture as the business is to a great extent recession-proof, with a critical upscale development.


India Contract Research Organization is one of the growing markets. The India Contract Research Organization market is majorly segmented into Drug Development/Clinical Trials, Drug Discovery and Post Marketing Services. Further on the bases of drug discovery services type the market is segmented into Clinical Services, Biology Services and Chemistry Services. 

The major factors is the low cost of CRO in developing countries like in India, increasing new players entering in the CRO market with resulting in high competition and better healthcare infrastructure and institutions in these countries and growing private funds and government initiatives in the region. India Contract Research Organization market statistical report published by Market Research future contains a brief overview of India Contract Research Organization market. 

The market has been segmented into Drug Development/Clinical Trials, Drug Discovery and Post Marketing Services. Further on the bases of drug discovery services type the market is segmented into Clinical Services, Biology Services and Chemistry Services. Drug Development/Clinical Trials accounted for the largest market share in 2016 and is expected to grow continuously during the forecasted period of 2017-2022. The report analyzed the India Contract Research Organization market and present systematic data of market share on the basis of segments and countries, and its growth rate for 2014 to 2017, along with forecast till 2022.



Wednesday, July 5, 2017

BIOCAD’s rituximab biosimilar to receive MA soon in India

In August 2017, BIOCAD will receive permanent market authorization in India, which represents a strategic milestone for BIOCAD's international expansion.


The 
Central Drugs Standard Control Organization(CDSCO) has recommended Acellbia, the first rituximab biosimilar made in Russia, for approval in India.

In August 2017, BIOCAD will receive permanent market authorization in India, which represents a strategic milestone for BIOCAD's international expansion.

Today, the Indian market for rituximab exceeds $40 m, with an annual growth of 8%. According to experts, this volume may reach $58 million in the next five years.

Meanwhile, India experiences low rituximab availability. Therefore, the Russian biosimilar marketed here will not only boost competition among the existing players, but will make this product available for larger numbers of patients with certain types of lymphomas and autoimmune disorders.


Sunday, June 25, 2017

Delay in 'Made in India' chikungunya vaccine, researchers seek government intervention

India offers a rare ray of hope for an indigenously-made vaccine against chikungunya, but delay in finding volunteers is impeding its development. 

With chikungunya spreading very fast in the country, researchers are seeking urgent government intervention for speedy completion of the vital clinical trials. 

Chikungunya is a dreaded infection transmitted through the bite of the mosquito. There is no known cure and till date, there is no vaccine anywhere in the world again .. 

The novel vaccine candidate against chikungunya crossed a big hurdle last year when Bharat Biotech, a Hyderabad-based vaccine pioneer, got permission to start human trials and the first human subjects received the vaccine a few months ago. 

The company says the phase-I trials will "evaluate the vaccine's safety, tolerability and immunogenicity. The placebo controlled study involving 60 healthy volunteers would test escalating doses of the vaccine in prime-boost regimen". 

Continue reading here: Source

Sunday, June 18, 2017

Evolving Pharmaceutical Ecosystem Transforms Clinical Trials and Research Outsourcing

Access to advanced research tools will expand growth opportunities for CRO participants, finds Frost & Sullivan's Transformational Health team

The clinical trials and research outsourcing (CRO) market is growing, leveraging the global pharmaceutical industry's urgent need to succeed in late clinical trials and build the pipeline of new molecules. While cost benefits, focus on core competencies, rise in innovative therapeutic options, and increased drug efficacy and safety norms will continue to encourage global pharma companies to outsource, CROs must increase their range of services to better serve, and become the preferred partner to, bio-pharmaceutical companies.

"Expanding CRO services into early stages of drugs, emergence of virtual biotech, out-licensing, and risk sharing between pharma and CROs are disrupting traditional business models," noted Transformational Health Research Analyst Sanjeev Kumar. "They are also opening up greater opportunities for CROs in terms of access to a huge market, newer areas such as commercial and post-launch, bioanalytical testing and development services, and partnerships with small-to-midsize biotech and virtual pharma customers."


Continue reading